RBC Capital Downgrades Sagent Pharmaceuticals (SGNT) to Sector Perform Following Takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction
July 11, 2016 2:30 AM EDTTransaction brings together two market leaders in generics with highly complementary product offerings
Marks a significant step in Nichi-Ikos international growth strategy through establishment of U.S. platform
TOKYO & SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Nichi-Iko Pharmaceutical Co., Ltd (TSE: 4541) and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) today announced that they have entered into a definitive merger agreement under which Nichi-Iko will acquire Sagent via an all-cash tender offer (the Tender Offer) followed by a second-step merger, for a total... More
